Clinical Education Series
01 / 12

Sex-Sensitive AUD Pharmacotherapy

Evidence-Based Adaptation Across the Reproductive Life Cycle

The Problem
02 / 12

The Male-Centric Paradigm

Historical Context

  • AUD historically studied in male populations
  • NIH 1993 mandate: include women in research
  • Slow translation to sex-stratified outcomes
  • Most trials: women < 50% enrollment

The Telescoping Effect
  • Women: faster progression to dependence
  • Lower absolute consumption
  • Higher medical consequences
  • "Sicker, quicker" trajectory

Pharmacokinetics
03 / 12

Biological Foundations

Absorption & Distribution

  • Slower gastric emptying → prolonged Tmax
  • Lower gastric ADH → higher BAC per drink
  • Higher body fat % → larger Vd for lipophilic drugs
  • Lower body water → higher peak concentrations

Metabolism

  • CYP3A4: generally higher in women
  • CYP1A2: typically lower in women
  • Lower GFR → reduced renal clearance
  • Hormonal fluctuations affect metabolism
FDA Medications
04 / 12

Naltrexone: Sex-Specific Evidence

Efficacy

  • Equal when adequately powered (COMBINE)
  • Early underpowered trials: W < M
  • LAI: efficacy in men, not women at high dose

Tolerability

  • Higher nausea in women (25.8% vs 16.3%)
  • More somnolence, sleep disturbances
  • Higher discontinuation rates
  • Luteal phase: ↑ sensitivity
Off-Label
05 / 12

Baclofen: Female Efficacy Signal

11×

Women on baclofen were 11 times more likely to achieve abstinence than men (ALPADIR trial).

Mechanism: Estrogen may increase GABA-B receptor sensitivity. Women with anxiety may particularly benefit from baclofen's anxiolytic properties.
Safety Alert
06 / 12

Topiramate: The Reproductive Trap

🚨 CRITICAL WARNING

  • FDA Category D: 3.3× oral cleft risk
  • CYP3A4 inducer: reduces OCP efficacy 18–30%
  • NEVER prescribe to women on OCPs alone
  • Require LARC (IUD, implant) or barrier methods
Reproductive Cycle
07 / 12

Life Cycle Adaptations

Menstrual Cycle

Luteal phase (days 24-28): Progesterone drop → reduced GABAergic tone → craving vulnerability

Pregnancy

Naltrexone preferred if medication indicated. Topiramate and disulfiram absolutely contraindicated.

Postpartum

Highest relapse risk. Naltrexone and acamprosate compatible with breastfeeding.

Menopause

Acamprosate and gabapentin excellent choices—spare the aging liver.

Decision Support
08 / 12

VALUES Matrix

Naltrexone

  • Efficacy: High (W = M)
  • Weight: Neutral
  • Pregnancy: Preferred

Acamprosate

  • Efficacy: High (W = M)
  • Weight: Neutral
  • Pregnancy: Alternative

Baclofen

  • Efficacy: Very High (W > M)
  • Weight: Neutral
  • Pregnancy: Avoid
Summary
09 / 12

Key Recommendations

1. Mandatory Screening

Screen all women of reproductive age for pregnancy intent before prescribing.

2. Dose Titration

"Start low, go slow" for naltrexone to overcome nausea barrier.

3. Contraceptive Vigilance

Never prescribe topiramate without verified LARC.

4. Baclofen Consideration

Prioritize for women with anxiety—emerging W > M efficacy signal.

Resources
10 / 12

Key Resources

Guidelines

  • ASAM National Practice Guideline
  • ACOG SUD in Pregnancy
  • SAMHSA TIP 49

Key Studies

  • COMBINE Study Secondary Analysis
  • BacALD/ALPADIR Trials
  • Quintrell 2024 Scoping Review
01 / 10